OMER Stock: Omeros Corporation Stock Price, Analysis & Insights
Get live omer stock price $7.87, comprehensive Omeros Corporation stock analysis, charts, news, and expert forecast. Real-time omer stock data and investment insights.
Loading chart...
Company Overview
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Company Information
- CEO
- Gregory A. Demopulos
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 202
Contact Information
- Website
- https://www.omeros.com
- Address
- The Omeros Building
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 2.52)
Business Model & Strategy
Omeros Corporation operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Gregory A. Demopulos, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Omeros Corporation competes in the Biotechnology within the broader Healthcare. With 535.6 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Omeros Corporation provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Omeros Corporation should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Omeros Corporation shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Omeros Corporation
- ⚠Investors should consider how Omeros Corporation fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
535.60M
P/E Ratio
-3.33
Beta
2.52
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 535.60M market capitalization
- Trading Volume: 4.82M shares traded today
- Price Range: 52-week range of $2.95 - $13.60
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Omeros Corporation
Omeros Corporation (OMER) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 535.60M, the company represents a significant player in its market. The stock is currently trading at $7.87 with a positivedaily change of 25.32%.
The company's 202 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -3.33, beta of 2.52, and 52-week price range from $2.95 to $13.60when evaluating investment opportunities.
Why Invest in Omeros Corporation?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Gregory A. Demopulos
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.